Cooperative Agreement W911QY1620002

This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on developing targeted antibiotic therapy strategies for Shigella infections among children in low-resource settings. The $746,813 award will support a multi-year study to characterize the impact of Shigella on diarrhea outcomes, evaluate the use of fecal biomarkers to identify Shigella cases, and...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,256,360 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, San Francisco (UCSF) to conduct the "The DOXY-PEP IMPACT Study". This multi-city longitudinal cohort study aims to: Evaluate the effectiveness and patterns of use of doxycycline as pre-exposure prophylaxis (DOXY-PEP) to reduce sexually transmitted infections (STIs) in men who have...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,563,642 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF) to conduct a randomized directly observed therapy (DOT) study to interpret clinical trials of doxycycline post-exposure prophylaxis (doxy-PEP) for bacterial sexually transmitted infections (STIs). The study aims to develop in-depth adherence measurement...

This federal Project Grant award, valued at $766,877.00 and issued by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports a randomized controlled trial to evaluate the efficacy of therapeutic drug monitoring (TDM) for linezolid in the treatment of rifampin-resistant tuberculosis (RR-TB). The primary goal is to determine if TDM can prevent premature discontinuation of linezolid, a critical medication for...

The University of California, San Diego (UCSD) has been awarded a $664,744 project grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The purpose of this 3-year award is to conduct a randomized Phase I/II pilot clinical trial to evaluate the safety, tolerability, feasibility, and efficacy of phage therapy in reducing recurrent urinary tract infections (UTIs) in...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $303,225 to The University of Iowa to research an engineered probiotic strain that could competitively exclude Salmonella bacteria from colonizing the intestinal epithelium of poultry. The overarching goal is to reduce Salmonella carriage in poultry, which would significantly improve food safety and decrease the...

This $108,916 Project Grant awarded by the National Institutes of Health Fogarty International Center (CFDA 93.989 - International Research and Research Training) will allow Dr. Clifford George Banda to characterize the pharmacokinetic and safety profiles of the antimalarial drugs lumefantrine and amodiaquine in two key target populations: African children with severe acute malnutrition and adults living with HIV on dolutegravir-based antiretroviral therapy. The study aims to inform the...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $587,318 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU). The funding supports the optimization of a next-generation antimalarial drug candidate, ELQ-596, to enable once-monthly oral prophylaxis in humans. Specifically, the research aims to enhance the structural features of ELQ-596 to improve its intrinsic anti-plasmodial activity,...

The University of Maryland, Baltimore was awarded a $2,002,422 Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research to further understand the protective immunological mechanisms associated with vaccination and infection from major human-restricted enteric bacterial pathogens, such as Salmonella and Shigella, in both children and adults. The research will...

This $1,373,790 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to optimize the structural features of the anti-malarial compound ELQ-596. The goal is to develop a next generation of ELQ compounds for once-monthly oral prophylaxis against malaria in humans. The research team, which includes experts in medicinal chemistry, malaria, molecular parasitology, biochemistry, structural biology,...